Immune checkpoint protein labeling for cancer immunotherapy enables precise tracking and functional analysis of regulatory proteins like PD-1 and CTLA-4. Techniques such as biotin labeling support ELISA, SPR, and FACS assays, offering high specificity and low background. These labeled proteins help researchers study immune modulation, screen therapeutic antibodies, and advance drug development targeting tumor immune evasion.
